Nomura/Instinet raised its price target on Redhill Biopharma (NASDAQ: RDHL) to $28.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

RedHill Biopharma (RDHL) Highlights Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's DiseaseAugust 1, 2018 8:17 AM RedHill Biopharma (RDHL) Reports Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s DiseaseJuly 30, 2018 7:07 AM Form 6-K RedHill Biopharma Ltd. For: Jul 30July 30, 2018 7:01 AM RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s DiseaseJuly 30, 2018 7:00 AM